Hematologic Oncology

Faith E. Davies, MD, discusses the research being done in patients with multiple myeloma who are refractory to lenalidomide.

Rajat Bannerji, MD, PhD, discusses the clinical activity of the bispecific antibody REGN1979 in patients with non-Hodgkin lymphoma.

Ankit Kansagra, MD, discusses updates with CAR T-cell therapy in multiple myeloma.

Larry Anderson, MD, PhD, discusses the phase II GRIFFIN trial examining the addition of daratumumab (Darzalex) to lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (D-RVd) in patients with multiple myeloma.

Srikanth Nagalla, MD, discusses the utility of direct oral anticoagulants in cancer-associated thrombosis.

Robert J. Kreitman, MD, discusses the long-term findings from the pivotal phase III trial with moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

Robert J. Kreitman, MD, senior investigator and head of the Clinical Immunotherapy Section in the Laboratory of Molecular Biology at the National Cancer Institute, discusses ongoing research with moxetumomab pasudotox-tdfk (Lumoxiti) in patients with hairy cell leukemia (HCL).

Michael L. Grossbard, MD, discusses the phase III DYNAMO study examining the use of duvelisib in the treatment of patients with indolent non-Hodgkin lymphoma.

The benefit of single-agent acalabrutinib continued well over 3 years after treatment initiation in patients with relapsed/refractory chronic lymphocytic leukemia.

Alvin H. Schmaier, MD, discusses the primary and secondary management of cancer-related thrombosis.

Joshua Brody, MD, discusses the utility of in-situ vaccines as a novel way to harness immune response and extend the reach of immunotherapy in patients with advanced-stage indolent non-Hodgkin lymphoma.

Corey S. Cutler, MD, MPH, FRCPC, discusses some of the novel preventive strategies against graft-versus-host disease.

Syed Rizvi, MD, discusses research efforts exploring brentuximab vedotin combinations in patients with Hodgkin lymphoma.

Brad S. Kahl, MD, outlines the available treatment options in indolent non-Hodgkin lymphoma, factors that may influence treatment selection, and promising agents on the horizon.

Brad Kahl, MD, discusses the efficacy of targeted agents across indolent lymphomas.

Aaron Goodman, MD, discusses the need for molecular subtyping in T-cell lymphomas.

Mohammad Maher Abdul-Hay, MD, discusses the future of targeted therapy in acute lymphoblastic leukemia.

Tania Jain, MBBS, discusses the potential for graft-versus-host disease as a complication of allogeneic stem cell transplant.

Alvin H. Schmaier, MD, discusses the secondary management of thrombosis in patients with hematologic malignancies.

Ruben Mesa, MD, and his patient Antje Hjerpe, who has been living with essential thrombocythemia for 35 years, share the challenges in diagnosing ET, the current state of treatment and ongoing research efforts, and resources Mesa recommends on educating both physicians and patients on myeloproliferative neoplasms and components of care.

This week we have collaborated with NYU Langone Health to highlight important topics facing oncologists today. Join us on Saturday, May 9, 2020 at 11 AM EDT.

Prapti Patel, MD, discusses data from the MEDALIST trial on the use of luspatercept-aamt in patients with low-risk myelodysplastic syndromes.

The approval of imatinib almost 20 years ago heralded the arrival of the targeted therapy era in oncology and thrust the ABL1 kinase into the limelight.

The China National Medical Products Administration has accepted an application for gilteritinib for the treatment of adult patients with FLT3 mutation–positive acute myeloid leukemia.

We recently traveled to Chicago, Illinois for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from Rush University Medical Center faculty.